8th Neuropsychiatric Drug Development Summit

The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum capturing advancements across discovery, preclinical, translational, clinical, and regulatory development of innovative neuropsychiatric therapeutics.

Over the 3-day agenda, you’ll join 150+ discovery, preclinical, translational, clinical, and regulatory leaders for deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics.

This year’s most anticipated discussions will focus on:

• Deciphering the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers
• New and innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically
• The efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy, and the groundbreaking progress in novel non-hallucinogenic neuroplastogens
• The latest advancements in new targets and mechanisms, including moving beyond atypical antidepressants and antipsychotics, to truly transform patient burdens

Additionally, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape.

Don’t miss out on this unique forum that’s spearheading a new era of more transformative mental health therapeutics.